PsiloThera, Inc. offering is now closed and is no longer accepting investments.

INVEST IN PSILOTHERA, INC. TODAY!

Psychedelic Healthcare Innovation

Psilothera is a pioneering mental health care company dedicated to creative, modern solutions to treat global healthcare concerns, including depression, anxiety, PTSD, eating disorders, addictions, Alzheimer’s, dementia, and more. We plan to deploy quantum technology to shorten the drug development time, which will give us an advantage over our competitors. With a focus on healing, hope, and compassion, we aim to change the paradigm of mental healthcare with their Psilocybin-based therapies.

This Reg CF offering is made available through StartEngine Capital, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.
PsiloThera, Inc.

$173,121.29 Raised

REASONS TO INVEST

Reasons Icon

Psilothera is stepping into the scene of major healthcare crisis by focusing on medical research breakthroughs and groundbreaking legalizations

Reasons Icon

The company is actively targeting a $100 billion market opportunity in Psilocybin healthcare

Reasons Icon

Psilothera is led by a battle tested management team with business model, strategy and plan driven by research and development

The Problem


The world is in the throes of a mental health crisis   


Recent estimates from the World Health Organization show that roughly 322 Million People suffer from Major Depression Disorder. In the US alone, 16 million people suffer from this debilitating disease. What’s worse is that up to a third of the people suffering from clinical depression are “treatment resistant,” meaning traditional antidepressants don’t treat them. This resistance is one of the reasons why 17.6 veterans commit suicide a day in the United States. With the current state of the mental healthcare industry, they have no other options for medication.



A recent Gallup poll shows that the pharmaceutical industry is the least trusted industry in America. Toxic industry norms, widespread corruption, as well as harsh side effects of mental health medicine have created a need for a viable alternative among patients and consumers. (Source





THE SOLUTION


Psilocybin-based therapy is revolutionizing the world of mental healthcare


Psilothera commits to providing new remedies for mental wellness by creating compounds for Psilocybin-based treatments. Psilocybin assisted therapy gives the patient the opportunity to fully engage in self-reflection and personal expression, ultimately shift emotional and behavior patterns.  




The technique used in Psilocybin assisted therapy is microdosing. Microdosing is the regular intake of very small quantities of psychedelic substances. Microdosing is beneficial because while there are minimal acute effects reported, these substances claim a range of long-term health and well-being benefits. We believe the fear of having a “bad trip” on Psilocybin makes microdosing a more approachable option for the millions of people suffering. 



THE MARKET


Vertical integration powered by quantum technology



Psilothera’s battle tested leadership team is made up of entrepreneurs, mental health professionals, and mushroom farmers. This team agrees on the same mission: be one of the first companies focused on developing Psilocybin-based therapeutics while deploying quantum technology. We are currently in the final stages of procuring a technology licensing agreement with a well-known quantum technology company, which will drastically reduce the development time as well as the cost of therapeutics. 






OUR TRACTION


Gaining momentum by the day


Breakthrough studies by reputable programs such as Journal of JAMA Psychiatry, Johns Hopkins Center for Psychedelic & Consciousness Research, Imperial College, and US National Library of Medicine National Institute of Health have all shown promising results on psychedelics’ ability to treat long-lasting depressive, PTSD, and anxiety symptoms with minimal side effects. 


Psilothera’s partnership with the Zoom Healthcare ISV Program to develop its tele-health mental health care video platform is paving the way for groundbreaking development in online Psilocybin-based treatment. 




Psilothera is pre-revenue and our Fungi Grow & Lab is in its pre-launch stage. Once launched, the lab will begin researching, growing, and developing 20 different types of Psilocybe Cubensis, providing us with a robust portfolio of therapeutic fungi. 


The varieties of mushrooms to be used in our formulations include Reishi, Lion’s Mane, Turkey Tail, Shiitake, Maitake, and Oyster. Reishi, for example, is being studied and used for its anticancer potential at the Memorial Sloan Kettering Cancer Center. Our Mushroom Nutraceutical product line for cancer patients is designed to support their current treatments program.



On a global scale, in November 2020, Oregon became the first state in the United States to legalize Psilocybin, allowing supervised use of psilocybin in a therapeutic setting.


Furthermore, voters around the country have decriminalized in Washington DC, Denver, Oakland, Ann Arbor, Houston, Somerset and Cambridge, MA so far. Psilothera projects widespread movement towards Legalization and Decriminalization by 2023.






WHY INVEST


The time to invest is now


A major paradigm shift is occurring in the healthcare sector. Breakthrough medical studies, a string of groundbreaking legalizations, and an unprecedented public openness to psychedelics has paved the road for Psilocybin-based therapy to be a legitimate alternative to pharmaceutical products. Psilothera aims to deploy this cutting edge medicine to establish itself as a beacon of hope, wellness, and compassion in the mental health market.


gif


Annual sales for antidepressants, ADHD, anxiety, and anti-addiction medications well exceed $30 billion, and an increasing number of studies are showing a potential for Psilocybin and other psychedelic-based therapies to be as or even more effective than their pharmaceutical counterparts, meaning potential billions in revenue. 


Our mushrooms aren't magic. They're therapeutic, backed by science. We believe they're the future of mental health treatment.





THE OFFERING MATERIALS MAY CONTAIN FORWARD-LOOKING STATEMENTS AND INFORMATION RELATING TO, AMONG OTHER THINGS, THE COMPANY, ITS BUSINESS PLAN AND STRATEGY, AND ITS INDUSTRY. THESE FORWARD-LOOKING STATEMENTS ARE BASED ON THE BELIEFS OF, ASSUMPTIONS MADE BY, AND INFORMATION CURRENTLY AVAILABLE TO THE COMPANY’S MANAGEMENT. WHEN USED IN THE OFFERING MATERIALS, THE WORDS “ESTIMATE,” “PROJECT,” “BELIEVE,” “ANTICIPATE,” “INTEND,” “EXPECT” AND SIMILAR EXPRESSIONS ARE INTENDED TO IDENTIFY FORWARD-LOOKING STATEMENTS, WHICH CONSTITUTE FORWARD LOOKING STATEMENTS. THESE STATEMENTS REFLECT MANAGEMENT’S CURRENT VIEWS WITH RESPECT TO FUTURE EVENTS AND ARE SUBJECT TO RISKS AND UNCERTAINTIES THAT COULD CAUSE THE COMPANY’S ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE CONTAINED IN THE FORWARD-LOOKING STATEMENTS. INVESTORS ARE CAUTIONED NOT TO PLACE UNDUE RELIANCE ON THESE FORWARD-LOOKING STATEMENTS, WHICH SPEAK ONLY AS OF THE DATE ON WHICH THEY ARE MADE. THE COMPANY DOES NOT UNDERTAKE ANY OBLIGATION TO REVISE OR UPDATE THESE FORWARD-LOOKING STATEMENTS TO REFLECT EVENTS OR CIRCUMSTANCES AFTER SUCH DATE OR TO REFLECT THE OCCURRENCE OF UNANTICIPATED EVENTS.




ABOUT

HEADQUARTERS

17 Cerchio Basso
Henderson, NV 89011
VALUATION

$50M

Psilothera is a pioneering mental health care company dedicated to creative, modern solutions to treat global healthcare concerns, including depression, anxiety, PTSD, eating disorders, addictions, Alzheimer’s, dementia, and more. We plan to deploy quantum technology to shorten the drug development time, which will give us an advantage over our competitors. With a focus on healing, hope, and compassion, we aim to change the paradigm of mental healthcare with their Psilocybin-based therapies.

TEAM

John Atanasio
John Atanasio
CEO and Founder

John is a Visionary and Serial Entrepreneur with significant Executive Management experience. He is an Advocate for Psilocybin Decriminalization & Legalization and Testified in Support of Psilocybin Decriminalization at a Session of the State of Hawaii Legislature debating SB:38 on February 2021. John has a Successful track record of developing and working with next generation web based platforms & technologies for Healthcare & Medical Industries: Electronic Medical Record (EMR) Technologies, e-RX Technologies, Online Physician Platforms & Patient Wellness App.

Jacquelyn Wright-Minogue
Jacquelyn Wright-Minogue
Advisor- Clinical Trials & Founder

Jacquelyn Wright-Minogue, MS, PMP has over 30 years of pharmaceutical industry experience. Jackie first joined Schering-Plough in the pathology area. She then moved onto basic research and clinical research in several therapeutic areas such as pathology, virology, allergy and immunology, oncology and rare diseases. Her cloning, RT-PCR and DNA sequencing knowledge and skills led her to an adjust professor teaching position at a Kean University where she taught master level courses in DNA sequencing. Feeling the need to get closer to the patient experience after 20 years in basic scientific research, Jackie leaves Schering-Plough/Merck, and moves onto Novartis to work on oncology trials. Working on clinical trials for medulloblastoma in children and basal cell carcinoma. The drug was approved by the FDA as sonidegib for locally advanced basal cell carcinoma. From big pharma, Jackie moved onto a small biotech company called Amicus Therapeutics where she quickly advanced to her current role as Sr. Director of Clinical Operations. Jackie helped spearhead and enrolled the largest ever trial in Pompe Disease in record time, keeping patients on study during a global pandemic. It is her life mission to get medication to those in need. During the pandemic more people are suffering from mental illness than ever before. Jackie believes that this unmet medical need could benefit from a healthier, natural option with less side effects than traditional medicine.

"Chaplain Chuck" Atanasio
"Chaplain Chuck" Atanasio
Director of Research, Psychologist, Retired Army Major, Chaplain & Behavioral Specialist

Chaplain Chuck will spearhead our clinical approach and shall develop our Veteran & Civilian Psilocybin Therapeutic Studies and Programs & Suicide Prevention Programs. Chaplain Chuck trained hundreds of military personnel once a year in suicide prevention for 16 years. He has also been Certified to Train First Responders on suicide intervention. An Iraqi Combat Vet, he has served 25 years in the military as an Army Chaplain and as a Behavioral Science Specialist. Chuck has a MSW Degree in Social Work from Marywood University and a MS in Experimental Psychology from Purdue University and a BA in Psychology from Seton Hall University. Notable Service of Achievement and Invaluable Experience: Awarded Bronze Star & GWOT Expeditionary Medal for Military Service, 2003-2004. GWOT=Global War on Terrorism. Operation Iraqi Freedom; Awarded General Petraeus Excellence in Combat Coin. Chaplain Chuck has provided compassionate spiritual needs assessments, care & counseling to increase the resiliency of hundreds of individuals, couples and families in: burn wards, combat operations, in-patient psychiatric wards critical incidents, emergency rooms, funeral homes, hospice, hospitals, memorials, military deployments and exercises, nursing homes, orphanages, prisons, relationship enhancement retreats and work office settings.

Michelle Pon Tell
Michelle Pon Tell
Head Therapist-Advisor

Michelle Pon Tell, Head Therapist, LCSW, MA, CCTP

Michelle is a Certified Clinical Trauma Professional, clinically trained in Somatic Experiencing, a method ideally suited to gently releasing the stress, anxiety, trauma and overwhelm trapped in one's body. This powerful modality allows clients to quickly resolve past emotional issues so they can move forward with a sense of joy and freedom.

Her experiences working with Hospice, as well as providing intensive in-home therapy to families, has allowed Michelle the humbling privilege of walking with all types of individuals through some of life's most difficult circumstances. Whatever your situation, she is available to meet you where you are and help you get to where you want to be.

Jan Rydfords
Jan Rydfords
Doctor- Medical Advisor

Dr. Rydfors received his Medical degree and specialization training from Stanford University Medical Center where he is an Adjunct Clinical Professor. Dr Rydfors has extensive experience in high risk Obstetrics, advanced fertility treatment and treatment of recurrent miscarriages. Over the last 30 years, Dr Rydfors has developed a successful multidisciplinary program to prevent recurrent miscarriages which attracts patients from all over the US. His interests include also autism prevention in pregnancy. He is the initial creator and current Co-Author of the popular “Handbook in Obstetrics, Gynecology and Infertility,” now in its sixth edition, the main handbook used by all Obstetricians and Gynecologists in training in the US. He was the founder of OBOnTheGo and EmbraceHerHealth which made the most complete medical grade pregnancy Mobile Apps when they came out and currently is a co-founder of EverDoc where powerful AI and Machine Learning is being used to optimize medical care. He is the Chief Medical Advisor for the American Pregnancy Association and acts as a Medical Advisor for several Silicon Valley Companies. He is the recipient of the Compassionate Doctor, Marquis who’s who in the world and Patient’s Choice award.

Holly Scott
Holly Scott
Director of Fungi Grow & Cultivation

Holly is the “Mushroom Queen” and will lead our grow operations and has extensive experience in this area of specialization. Holly has curated a portfolio of (20) Psilocybe species spores to launch an extensive Psilocybe grow operation.

Anthony Baldassari
Anthony Baldassari
Behavioral Analyst

Anthony shall we be part of our team that shall be working with high risk patients. Anthony recently Earned his MA in Behavioral Analysis from Florida Institute of Technology and previously earned his BA from the University of Colorado in Neuroscience and Psychology. Anthony has worked at RBT since 2017 and has worked with individuals of all ages with a wide range neurodevelopment disorders. His research Interest include the use of ABA with individuals with dramatic brain injuries and individuals with co-morbid mental health and neurodevelopment disorders diagnosis.

Adam Bell
Adam Bell
Creative Director- Web Design & Strategy

Adam Bell has been designing and developing website projects for twenty five years. He has worked on a variety of projects in the world of e-commerce and entertainment. Current projects are with Cafe du Monde, Tattoo Tequila, Skull + Monarch Auctions + Galleries and PowerAnimal Pet Foods. In the past he’s worked with the likes of Ovation TV, Amblin Partners, Tender Greens and the Ford Motor Company among many others. He’s worked with everyone from small startups to multi-national corporations. Adam is going to help spearhead the development of a groundbreaking e-Mental Health initiative that will provide relief from suffering for millions a people.

Dan Vosler
Dan Vosler
Director of IT

Daniel is Linux Systems Engineer and has been recently been working in the academic research space with some of the best computer science programs in the world. Daniel believes we have a core responsibility to steward our resources to benefit humanity; especially to those in need of care.

Leif Rydfors
Leif Rydfors
Patient Advocate - Spokesperson

Leif’s passion for healing stems from the challenges he faced during a life-long battle with debilitating depression and anxiety. His tenacity and desire for emotional relief led him to seek treatment. After reading about the cutting-edge research that was done in John’s Hopkins University and Imperial College in London his intrigue led him to action. His psilocybin treatment along with his spirituality has clearly shown him that we were put here on this planet to serve. His biggest desire is for global awakening and he feels compelled to help people navigate through the deep waters of true self-discovery. Leif is determined and compelled to offer the guidance of his experience to transcend the pain and suffering of others in need.

Spike Humer
Spike Humer
Business Development & Strategy

Spike Humer shall advise Psilothera in areas of Business Development and Strategy. Spike is widely-recognized as a thought-leader and world-renowned expert in leading and inspiring companies, organizations, and individuals to achieve more, have more, and be more. He’s been called the “mentor’s mentor” and is highly regarded as a master marketing strategist and performance acceleration expert. Spike serves as a trusted advisor and performance consultant to entrepreneurs and individuals from virtually every walk-of-life and in countless industries. He is an acclaimed author, speaker, thought-leader, and creator of “The 10 Day Turnaround Methodologies”, “Rapid Success Technologies”, and “The Overnight Entrepreneur” seminars, book, and workshop series.

Howard "Mystro' Stroman
Howard "Mystro' Stroman
Business Development & Strategy

"Mystro” shall focus on opportunities to drive growth via strategic partners and alliances.

Professionally Mystro is a. Music & Entertainment Industry Executive and iconic Vegas Music Director & Performer. He is a serial entrepreneur with business interests in the areas of Music Production, Internet + Technology, Craft Spirits, Cannabis, CBD & Quantum Technology.

Glen Biondi, Esq.
Glen Biondi, Esq.
Legal Advisor

Mr. Biondi obtained his Law Degree from Thomas Jefferson School of Law in San Diego, California and has been practicing law in California since 2000. Mr. Biondi shall advise Psilothera on wide array of Corporate legal matters. Prior to his Law Career he held positions in the Financial Services Industries and also he owned his own Contracting company. However, after undergoing a double-lung transplant in 1993, he was forced to change careers and eventually leading Glen to his career in Law.

Ed Galisewski
Ed Galisewski
Spiritual Advisor

Ed Galisewski has spent his entire career working in the field of Pharmaceutical sales. 29 years as a Virology/HIV Sales rep for Abbvie selling cutting edge Protease Inhibitors and now the last 5 years as the Regional Account Manager for Walgreens Specialty Pharmacy division covering several states. Ed has also served for 35 years as a Lay Pastor for several large suburban churches as a Men’s Ministry Director. His passion has always been about getting men together to talk freely about their life struggles and help them wrestle with their questions about faith. Ed is the author of two books that explore the concept of why people walk away from religion. “A Simpler Faith” and “Simplifying Religion” are his two book titles. His underlying goal for both books is to bring people back to faith in a world where Religion seems to be pushing people away form it.

Anthony Amatucci
Anthony Amatucci
Legislative Analyst

Anthony shall act as our legislative analyst and activist to promote the Legalization of Psilocybin for use in therapeutic settings. Anthony has several years of experience working for former U.S. Rep. Leonard Lance of NJ and Senator Tom Kean and his issue coverage and focus was Healthcare, Infrastructure and Taxes.

TERMS

PsiloThera, Inc.
Overview
PRICE PER SHARE
$5
DEADLINE
Mar 19, 2022
VALUATION
$50M
AMOUNT RAISED
$173,121.29
Breakdown
MIN INVESTMENT
$500.00
MAX INVESTMENT
$107,000.00
MIN NUMBER OF SHARES OFFERED
2,000
OFFERING TYPE
Equity
ASSET TYPE
COMMON
SHARES OFFERED
Common Stock
MAX NUMBER OF SHARES OFFERED
1,000,000

Maximum Number of Shares Offered subject to adjustment for bonus shares


Company

:

PsiloThera, Inc.

Corporate Address

:

17 Cerchio Basso, Henderson, NV 89011

Offering Minimum

:

$10,000.00

Offering Maximum

:

$5,000,000.00

Minimum Investment Amount

(per investor)

:

$500.00











Terms


Offering Type

:

Equity

Security Name

:

Common Stock

Minimum Number of Shares Offered

:

2,000

Maximum Number of Shares Offered

:

1,000,000

Price per Share

:

$5.00

Pre-Money Valuation

:

$50,000,000.00











*Maximum Number of Shares Offered subject to adjustment for bonus shares. See Bonus info below. Note these perks do stack with the other offering perks. You will only receive the highest level bonus share perk you are eligible for.

Company Perks*

Time-Based Perks

Friends & Family Bonus

Invest in the first 72 hours and receive 10% bonus shares.

Amount-Based Perks

Tier 1: $50,000+

Invest $50,000 or more and receive 5% bonus shares

Tier 2: $75,000+

Invest $75,000 or more and receive 7% bonus shares

Tier 3: $100,000+

Invest $100,000 or more and receive 10% bonus shares

*All perks occur when the offering is completed.

The 10% StartEngine Owners' Bonus

Psilothera will offer 10% additional bonus shares for all investments that are committed by investors that are eligible for the StartEngine Crowdfunding Inc. OWNer's bonus.

This means eligible StartEngine shareholders will receive a 10% bonus for any shares they purchase in this offering. For example, if you buy 100 shares of Common Stock at $5.00 / share, you will receive 110 shares of Common Stock, meaning you'll own 110 shares for $500. Fractional shares will not be distributed and share bonuses will be determined by rounding down to the nearest whole share.

This 10% Bonus is only valid during the investors' eligibility period. Investors eligible for this bonus will also have priority if they are on a waitlist to invest and the company surpasses its maximum funding goal. They will have the first opportunity to invest should room in the offering become available if prior investments are cancelled or fail.

Investors will only receive a single bonus, which will be the highest bonus rate they are eligible for.

Irregular Use of Proceeds

The Company will not incur any irregular use of proceeds.

ALL UPDATES

03.22.22

Psilothera + PolarisQB Sign Agreement to Launch Quantum, Ai + Machine Learning Technologies for Drug Discovery Platform.

Psilothera Important Update 

Thanks to all Investors 

Psilothera + PolarisQB Sign Agreement to Launch Quantum, Ai + Machine Learning Technologies for Drug Discovery Platform.
Our treatment focus is Mental Illnesses and Cognitive Diseases.


According to Psilothera CEO, John Atanasio, "Polaris QB is an important Strategic Relationship & Resource of Psilothera's Drug Discovery & Development Platform."
Atanasio stated , "We shall deploy Polaris QB's Quantum Computing ,Ai + Machine Learning Technologies to identify unique opportunities for molecular discovery."

According to PolarisQB,
"We have built the first ever drug discovery platform using a quantum computer, making the discovery process ten times faster. Our platform and technology allow us to scan billions of molecules from a large chemical space, while keeping costs efficient.Without the need for multiple optimization cycles, we find the same (or better) molecules faster utilizing Quantum Computing, artificial intelligence, and machine learning."

03.18.22

Utah Senate Approved Psychedelic & Mental Health Bill - sent to Governor

Utah Senate on Friday approved a psychedelic and mental health bill that would create a Mental Illness Psychotherapy Drug Task Force to study and make recommendations on the therapeutic potential of psychedelic drugs. The bill, which is now heading to the governor’s desk for a signature, would also establish possible regulations for the legal use of psychedelic drugs Source Bezinga

Utah is added to a list of States that have recently intiated a legislative process that includes: California, New York, Florida Hawaii. Oregon has already decriminalized and legalized for Therapeutic use. Denver, Houston, Washington DC are among the earliest cities  to decriminalize.

03.17.22

Psilothera Drug Discovery Pipeline- Target Receptors


IMG_6636.jpeg

Phase 1  Drug  Discovery Platform 

Diagnosis/ Serotonin Receptor (s)Targets

PTSD: 5HT2A

DEPRESSION: 5HT2AR, 5HT2A

ANXIETY: 5HT2A, 5HT1A, 5HT2C

ANOREXIA NERVOSA:5-HT2A, 5-HT1A, 5-HT2C

ANXIETY CO-MORBIDITY: 5HT2A, 5HT1A, 5HT2C

DEPRESSION CO-MORBIDITY: 5HT2AR, 5HT2A

OCD: 5HT1A, 5HT2A, 5HT2C

ADDICTIONS: 5HT2AR

AUTISTIC SPECTRUM DISORDER: 5-HT2A, 5-HT1A

ANXIETY CO-MORBIDITY: 5HT2A, 5HT1A, 5HT2C

SUBSTANCE USE DISORDER:5HT2A, 5HT2C

ANXIETY CO-MORBIDITY: 5HT2A, 5HT1A, 5HT2C

ALCOHOL USE DISORDER: 5HT2A

TOBACCO USE DISORDER: 5HT2A   

END-OF-LIFE ANXIETY: 5HT2A, 5HT1A, 5HT2C

ALZHEIMER’S, DEMENTIA, COGNITIVE DECLINE: 5HT2A-R

Data currently being collected on Cocaine, Opioids and Methamphetamine

Chuck Atanasio, Director of Research



01.06.22

Notice of Material Change in Offering

[The following is an automated notice from the StartEngine team].

Hello! Recently, a change was made to the PsiloThera, Inc. offering. Here's an excerpt describing the specifics of the change:


The issuer is extending their campaign 59 days to 03/18/2022.


When live offerings undergo changes like these on StartEngine, the SEC requires that certain investments be reconfirmed. If your investment requires reconfirmation, you will be contacted by StartEngine via email with further instructions.

12.13.21

Psilothera & PsyRx Sign Important Agreement to Develop Natural Psychedelic Compounds

Hi Psilothera Investors,

Important Announcement 

Psilothera & PsyRx Sign Agreement to Develop Natural Psychedelic Compounds.

PsyRx labs are located at Hebrew University in Tel Aviv, Israel and are licensed to develop  naturally sourced Psychedelic Compounds. We shall collaborate with PsyRx to create GMP-Standard naturally sourced (Not Synthesized) Psilocybin, Ibogaine and other Psychedelic compounds when available using PsyRx’s Agro-Medical Bio Reactor.

Psilothera shall utilize these compound to develop innovative Therapeutics and treatments for Mental Illnesses and Cognitive Diseases.

John Atanasio, CEO 

12.07.21

Psilothera Signs Agreement with Famous Shaman Inka Medicine Men to launch a healing retreat in Cuzco-Machu Picchu

Hi Psilothera Investors,

Psilothera gaining great traction in the market after our Wonderland- Miami Sponsorship. We are proud to announce this important company opportunity.

Psilothera is expanding into additional areas of Psychedelics beyond Psilocybin and is now looking at integrating  other treatment options such as Ketamine, MDMA, DMT and LSD. The company plans to apply for a DEA Schedule  1 license for research and manufacturing.

Psilothera  has signed an Agreement with Famous Shaman Inka Medicine Men  to launch a Psilothera healing retreat in Cuzco-Machu Picchu.

Psilothera has exclusivepartnered with internationally recognized Shaman Inka  Medicine Man K’uychi  Florez Zevallos and his Son Luciano  Florez Qquesihuallpa whom  is a Psychologist and Shaman Inka Medicine Man. 

K´uychi (Called Rainbow in his native Inka tongue “Quechua”) Born in Cusco, Peru. K’uychi holds an authentic blood and Inka lineage. K´uychi is a Shaman Inka Medicine Man, spiritualist, mystic, historian, researcher, poet and Peruvian politician. Since 1987, he has developed conferences and workshops throughout Asia, America and Europe. He is a University Professor, Master in Sciences who investigates and practices alternative therapies in a transpersonal, shamanic and holistic context. For the last 20 years, he´s been taking many groups of people to the jungle of Peru, leading them in shamanic experiences to treat and cure their mental and emotional illnesses, using the ancient jungle medicine, the sacred vine Ayahuasca DMT. Hundreds of people have awaken new states of consciousness, experienced a spiritual growth, enjoyed a new wellbeing and have discovered the real meaning of transcendence in their lives through the ceremonies and sacred rituals led by him. Nowadays K´uychi dedicates his great efforts to achieve the legitimacy of the legal therapeutic use of the DMT, and to stop the stigmatization of this divine plant that Mother Nature “Pachamama” with her immense love, has given to us, to whole humanity. His life’s mission is to spread the wisdom and medicine of the ancient Inka healers in all over the world. As shamans, we consider that DMT “The molecule of God” is one of the most powerful psychedelic that exist, its healing properties are limitless. DMT not only reaches your mind, goes even further into your heart and soul.

Please support our efforts and invest!

John Atanasio, CEO

12.01.21

Psilothera CEO John Atanasio to Speak at The Cannabis Investment Summit.- Feb 2nd

Hi Psilothera Investors

Psilothera CEO John Atanasio to Speak  at The Cannabis Investment Summit.- Feb 2nd.   Happy to  be invited and this gives Psilothera  another platform to share our story.

John Atanasio, CEO


12.01.21

Notice of Funds Disbursement

[The following is an automated notice from the StartEngine team].

Hello!

As you might know, PsiloThera, Inc. has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in PsiloThera, Inc. be on the lookout for an email that describes more about the disbursement process.


This campaign will continue to accept investments until its indicated closing date.


Thanks for funding the future.

-StartEngine

11.30.21

Psilothera to Present at the H.C. Wainwright 2nd Annual Psychedelics Virtual Conference - December 6, 2021.

Hi Startengine Investors,

Psilothera to Present at the H.C. Wainwright 2nd Annual Psychedelics Virtual Conference - December 6, 2021.

This is a great platform to share our story.

We have over 400 investors watching on the Startengine.

We have outstanding momentum and please invest now.

John Atanasio, CEO


11.23.21

Psilothera's CEO John Atanasio on Stage at Wonderland Miami 2021-Video

Hi StartEngine  Investors

Psilothera's  CEO John Atanasio on Stage at Wonderland Miami 2021 Video

https://youtu.be/P3BUv9HRRIw


REWARDS

Multiple investments in an offering cannot be combined to qualify for a larger campaign perk. Get rewarded for investing more into PsiloThera, Inc..

$500.00

StartEngine Owner’s Bonus

This offering is eligible for the StartEngine Owner’s 10% Bonus program. For details on this program, please see the Offering Summary section below.

$50,000.00

Tier 1: $50,000+

Invest $50,000 or more and receive 5% bonus shares

$75,000.00

Tier 2: $75,000+

Invest $75,000 or more and receive 7% bonus shares

$100,000.00

Tier 3: $100,000+

Invest $100,000 or more and receive 10% bonus shares

JOIN THE DISCUSSION













0/2500

HOW INVESTING WORKS

Cancel anytime before 48 hours before a rolling close or the offering end date.

WHY STARTENGINE?

REWARDS

We want you to succeed and get the most out of your money by offering rewards and memberships!

SECURE

Your info is your info. We take pride in keeping it that way!

DIVERSE INVESTMENTS

Invest in over 200 start-ups and collectibles!

With Regulation A+, a non-accredited investor can only invest a maximum of 10% of their annual income or 10% of their net worth per year, whichever is greater. There are no restrictions for accredited investors.

With Regulation Crowdfunding, non-accredited investors with an annual income or net worth less than $124,000, are limited to invest a maximum of 5% of the greater of those two amounts. For those with an annual income and net worth greater than $124,000, he/she is limited to investing 10% of the greater of the two amounts.

At the close of an offering, all investors whose funds have “cleared” by this time will be included in the disbursement. At this time, each investor will receive an email from StartEngine with their Countersigned Subscription Agreement, which will serve as their proof of purchase moving forward.

Please keep in mind that a company can conduct a series of “closes” or withdrawals of funds throughout the duration of the campaign. If you are included in that withdrawal period, you will be emailed your countersigned subscription agreement and proof of purchase immediately following that withdrawal.

StartEngine assists companies in raising capital, and once the offering is closed, we are no longer involved with whether the company chooses to list shares on a secondary market, or what occurs thereafter. Therefore, StartEngine has no control or insight into your investment after the close of the live offering. In addition, we are not permitted to provide financial advice. You may want to contact a financial professional to discuss possible investment outcomes.

For Regulation Crowdfunding, investors are able to cancel their investment at any point throughout the campaign up until 48 hours before the closing of the offering. Note: If the company does a rolling close, they will post an update to their current investors, giving them the opportunity to cancel during this timeframe. If you do not cancel within this 5-day timeframe, your funds will be invested in the company, and you will no longer be able to cancel the investment. If your funds show as ‘Invested’ on your account dashboard, your investment can no longer be canceled.

For Regulation A+, StartEngine allows for a four-hour cancelation period. Once the four-hour window has passed, it is up to each company to set their own cancelation policy. You may find the company’s cancelation policy in the company’s offering circular.

Once your investment is canceled, there is a 10-day clearing period (from the date your investment was submitted). After your funds have cleared the bank, you will receive your refund within 10 business days.

Refunds that are made through ACH payments can take up to 10 business days to clear. Unfortunately, we are at the mercy of the bank, but we will do everything we can to get you your refund as soon as possible. However, every investment needs to go through the clearing process in order to get sent back to the account associated with the investment.

Both Title III (Regulation Crowdfunding) and Title IV (Reg A+) help entrepreneurs crowdfund capital investments from unaccredited and accredited investors. The differences between these regulations are related to the investor limitations, the differing amounts of money companies are permitted to raise, and differing disclosure and filing requirements. To learn more about Regulation Crowdfunding, click here, and for Regulation A+, click here.

RAISED
$173,121.29
INVESTORS
164
MIN INVEST
$500.00
VALUATION
$50M

@ 2022 All Rights Reserved

Apple Store Logo

Get To Know Us

Our Team

Careers

Blog

Important Message

IN MAKING AN INVESTMENT DECISION, INVESTORS MUST RELY ON THEIR OWN EXAMINATION OF THE ISSUER AND THE TERMS OF THE OFFERING, INCLUDING THE MERITS AND RISKS INVOLVED. INVESTMENTS ON STARTENGINE ARE SPECULATIVE, ILLIQUID, AND INVOLVE A HIGH DEGREE OF RISK, INCLUDING THE POSSIBLE LOSS OF YOUR ENTIRE INVESTMENT.


www.StartEngine.com is a website owned and operated by StartEngine Crowdfunding, Inc. (“StartEngine”), which is neither a registered broker-dealer, investment advisor nor funding portal.


Unless indicated otherwise with respect to a particular issuer, all securities-related activity is conducted by regulated affiliates of StartEngine: StartEngine Capital, LLC, a funding portal registered here with the US Securities and Exchange Commission (SEC) and here as a member of the Financial Industry Regulatory Authority (FINRA), or StartEngine Primary, LLC, a broker-dealer registered with the SEC and FINRA/SIPC . You can review the background of our broker-dealer and our investment professionals on FINRA’s BrokerCheck here. StartEngine Secondary is an alternative trading system regulated by the SEC and operated by StartEngine Primary, LLC, a broker dealer registered with the SEC and FINRA. StartEngine Primary, LLC is a member of SIPC and explanatory brochures are available upon request by contacting SIPC at (202) 371-8300.


Investment opportunities posted and accessible through the site are of three types:


1) Regulation A offerings (JOBS Act Title IV; known as Regulation A+), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Primary, LLC (unless otherwise indicated). 2) Regulation D offerings (Rule 506(c)), which are offered only to accredited investors. These offerings are made through StartEngine Primary, LLC. 3) Regulation Crowdfunding offerings (JOBS Act Title III), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Capital, LLC. Some of these offerings are open to the general public, however there are important differences and risks.


Any securities offered on this website have not been recommended or approved by any federal or state securities commission or regulatory authority. StartEngine and its affiliates do not provide any investment advice or recommendation and do not provide any legal or tax advice with respect to any securities. All securities listed on this site are being offered by, and all information included on this site is the responsibility of, the applicable issuer of such securities. StartEngine does not verify the adequacy, accuracy or completeness of any information. Neither StartEngine nor any of its officers, directors, agents and employees makes any warranty, express or implied, of any kind whatsoever related to the adequacy, accuracy, or completeness of any information on this site or the use of information on this site. See additional general disclosures here.


By accessing this site and any pages on this site, you agree to be bound by our Terms of use and Privacy Policy, as may be amended from time to time without notice or liability.


Canadian Investors Investment opportunities posted and accessible through the site will not be offered to Canadian resident investors. Potential investors are strongly advised to consult their legal, tax and financial advisors before investing. The securities offered on this site are not offered in jurisdictions where public solicitation for offerings is not permitted; it is solely your responsibility to comply with the laws and regulations of your country of residence.


California Investors Only – Do Not Sell My Personal Information (800-317-2200). StartEngine does not sell personal information. For all customer inquiries, please write to contact@startengine.com.


StartEngine’s Reg A+ offering is made available through StartEngine Crowdfunding, Inc. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. For more information about this offering, please view StartEngine’s offering circular and risk associated with this offering.